BioMarin Raises 2025 Revenue Guidance as PALYNZIQ and VOXZOGO Sales Climb 20%
Reuters
Oct 28
BioMarin Raises 2025 Revenue Guidance as PALYNZIQ and VOXZOGO Sales Climb 20%
BioMarin Pharmaceutical Inc. reported operating cash flows totaling $369 million for the third quarter of 2025, and $728 million in year-to-date operating cash flows. Total cash, cash equivalents, and investments were $2.0 billion as of September 30, 2025, compared to $1.66 billion at December 31, 2024. The company updated its 2025 full-year financial guidance to reflect acquired in-process research and development charges of $221 million on a pre-tax basis related to the acquisition of Inozyme. The company also revised its Non-GAAP Operating Margin and Non-GAAP Diluted EPS guidance to include the impact of these charges. Weighted-average diluted shares outstanding for Non-GAAP Diluted EPS guidance is approximately 200 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF07455) on October 27, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.